Logo - Ocular Services On Demand

Publication Reference Index

The majority of our work involves studies that support the development of new ocular therapies and devices.  We have also participated in investigative studies that have advanced the field of preclinical development.  You may also filter for Development phase, (e.g., Safety) ophthalmology discipline (e.g., ocular imaging) and therapeutic class (e.g., Gene and Cell therapies).

Filter Results by...

Investigation Type Development Phase Therapy Class Discipline(s)
Durysta
Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs 		Approved Therapy Investigative Sustained Release Implant
  • Ophthalmic Exam
 Detail

Durysta
Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs

Vet Ophthalmol. 2018 Jul;21(4):376-381. doi: 10.1111/vop.12522. Epub 2018 Feb 19.

ABSTRACT

OBJECTIVE: To determine the effect of a bimatoprost sustained-release intracameral implant (Bimatoprost SR) on episcleral venous pressure (EVP) in normal dogs.

METHODS: Normotensive beagle dogs were randomized to receive Bimatoprost SR 30 μg (n = 7) or sham injection (needle insertion only, n = 7) in one eye on day 1. EVP was measured with an episcleral venomanometer through day 65. Episcleral aqueous outflow vessels were identified using fluorescence imaging following intracameral injection of indocyanine green in one additional animal. A separate cohort of dogs that had been trained for conscious intraocular pressure (IOP) measurements received Bimatoprost SR 30 μg (n = 8) in one eye; IOP was evaluated through day 66.

RESULTS: Baseline mean EVP was 10.0 mmHg in the Bimatoprost SR group and 10.4 mmHg in the sham group. Eyes treated with Bimatoprost SR exhibited a transient increase in mean EVP that peaked at day 8, followed by a decrease to levels below baseline. From day 29 to day 65, the change in mean EVP from baseline ranged from -2.4 to -3.9 mmHg (P < 0.05 vs. sham). Baseline mean IOP in eyes treated with Bimatoprost SR was 14.9 mmHg, and a steady IOP reduction was maintained through day 66. Bimatoprost SR-treated eyes exhibited a selective, sustained dilation of aqueous outflow vessels that was not observed in sham-treated eyes.

CONCLUSIONS: In normal dogs, Bimatoprost SR was associated with a transient increase in EVP followed by a sustained decrease. Changes in EVP were accompanied by a sustained dilation of aqueous outflow vessels.

PMID:29457333 | DOI:10.1111/vop.12522

Publication Authors
Susan S Lee, James Burke, Jie Shen, Alexandra Almazan, Werhner Orilla, Patrick Hughes, Jane Zhang, Huajiang Li, Craig Struble, Paul E Miller, Michael R Robinson
Full Publication
Durysta
Nonclinical pharmacokinetic and pharmacodynamic assessment of bimatoprost following a single intracameral injection of sustained-release implants 		Approved Therapy PK/PD Sustained Release Implant
  • Ophthalmic Exam
 Detail

Durysta
Nonclinical pharmacokinetic and pharmacodynamic assessment of bimatoprost following a single intracameral injection of sustained-release implants

 Translational Vision Science & Technology, 9(4), pp.20-20

Publication Authors
Shen, J., Robinson, M.R., Struble, C. and Attar, M., 2020
Full Publication